Daxdilimab is an investigational human immunoglobulin G subclass 1 monoclonal antibody that binds to immunoglobulin-like transcript 7, resulting in a targeted depletion of plasmacytoid dendritic cells associated with inflammation and skin lesions in cutaneous lupus erythematosus